As a single agent, MTX-531 could be envisioned to have a role in the treatment of not only HSNCC but also squamous lung cancers59, as well as a subset of triple-negative breast cancers driven by EGFR and PI3K60. The gene discussed is EGFR; the disease is triple-negative breast carcinoma.